158 related articles for article (PubMed ID: 3791561)
1. Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer.
Sulkes A; Gez E; Pfeffer MR; Catane R; Isacson R; Biran S
Cancer Chemother Pharmacol; 1986; 18(2):162-7. PubMed ID: 3791561
[TBL] [Abstract][Full Text] [Related]
2. Adriamycin (doxorubicin), vinblastine, and mitomycin C combination chemotherapy in refractory breast carcinoma.
Luikart SD; Witman GB; Portlock CS
Cancer; 1984 Oct; 54(7):1252-5. PubMed ID: 6467151
[TBL] [Abstract][Full Text] [Related]
3. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
[TBL] [Abstract][Full Text] [Related]
4. First, second and third line chemotherapy programs in metastatic breast carcinoma.
Rizel S; Sulkes A; Gez E; Brufman G; Biran S
Isr J Med Sci; 1981; 17(9-10):946-53. PubMed ID: 6171542
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy in metastatic tumors of unknown origin. 5-Fluorouracil, adriamycin and mitomycin C for adenocarcinomas and adriamycin, vinblastine and mitomycin C for anaplastic carcinomas.
Sulkes A; Uziely B; Isacson R; Brufman G; Biran S
Isr J Med Sci; 1988; 24(9-10):604-10. PubMed ID: 3204009
[TBL] [Abstract][Full Text] [Related]
6. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
8. Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
Kolarić K; Vukas D; Potrebica V
Tumori; 1989 Apr; 75(2):132-6. PubMed ID: 2741218
[TBL] [Abstract][Full Text] [Related]
9. CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.
Kolarić K; Roth A; Vukas D; Cervek J
Cancer Chemother Pharmacol; 1984; 13(2):142-4. PubMed ID: 6380789
[TBL] [Abstract][Full Text] [Related]
10. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone.
Tannir N; Yap HY; Hortobagyi GH; Hug V; Buzdar AU; Blumenschein GR
Cancer Treat Rep; 1984; 68(7-8):1039-41. PubMed ID: 6547638
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.
Kolarić K; Potrebica V; Vukas D; Mechl Z; Sopkova B
J Cancer Res Clin Oncol; 1988; 114(3):301-5. PubMed ID: 3164312
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy induces regression of brain metastases in breast carcinoma.
Rosner D; Nemoto T; Lane WW
Cancer; 1986 Aug; 58(4):832-9. PubMed ID: 3755076
[TBL] [Abstract][Full Text] [Related]
13. cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study.
Kolarić K; Tomek R
Tumori; 1990 Oct; 76(5):472-5. PubMed ID: 2256193
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide, methotrexate,5-fluorouracil, alternating with adriamycin and mitomycin C in metastatic breast cancer: a pilot study.
Cruciani G; Tienghi A; Molinari AL; Fiorentini G; Rosti G; Turci D; Marangolo M
Tumori; 1987 Jun; 73(3):303-7. PubMed ID: 3111046
[TBL] [Abstract][Full Text] [Related]
15. Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil.
Colozza M; Tonato M; Grignani F; Davis S
Cancer; 1988 Jul; 62(2):262-5. PubMed ID: 3383126
[TBL] [Abstract][Full Text] [Related]
16. Adriamycin, vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma.
Harding M; Sangster G; Milsted RA; Kaye SB; Calman KC
Med Oncol Tumor Pharmacother; 1988; 5(2):125-8. PubMed ID: 3412036
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.
Joensuu H; Holli K; Heikkinen M; Suonio E; Aro AR; Hietanen P; Huovinen R
J Clin Oncol; 1998 Dec; 16(12):3720-30. PubMed ID: 9850014
[TBL] [Abstract][Full Text] [Related]
18. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W
Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353
[TBL] [Abstract][Full Text] [Related]
19. Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA).
Shipp SK; Muss HB; Westrick MA; Cooper MR; Jackson DV; Richards FC; White DR; Stuart JJ; Christian RM; Ramseur W
Cancer Chemother Pharmacol; 1983; 11(2):130-3. PubMed ID: 6354509
[TBL] [Abstract][Full Text] [Related]
20. Short-term chemotherapy of poor-prognosis metastatic breast cancer with three non-cross resistant chemotherapy regimens. A Southwest Oncology Group Study.
Ahmann FR; Pugh R
Cancer; 1987 Jan; 59(2):239-44. PubMed ID: 3100013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
